Inês Francisco

Dr. Inês Francisco

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2006 in Gut
Verified
Journal Article
Closed access
PDF file
MSM Salazar
M Salazar
ABA Barata
A Barata
SAS André
S André
JVJ Venâncio
J Venâncio
IFInês Francisco
Inês Francisco
CNC Nobre-Leitão
C Nobre-Leitão
We report a case of a 68 year old woman with multiple local recurrences of a rectal GIST, first operated on 13 years earlier, and who now presented with four adjacent masses located in the rectovaginal septum and no distant metastasis. Molecular analysis identified a 6 bp deletion in exon 11 of the c-kit proto-oncogene. As curative surgery would have implied abdominoperineal resection with permanent colostomy, treatment with imatinib at a standard dose (400 mg/day) was started. Response to treatment was evaluated using endorectal ultrasound and magnetic resonance imaging every three months. Quantification of tumour mass was obtained by adding the products of two perpendicular axes of the two major lesions. Maximal response was obtained at nine months, which was maintained after 12 months of treatment. At that time, total tumour mass reduction was 83%, which was enough to allow rectal resection with a coloanal anastomosis (fig 1A, B). Pathological analysis of the surgical specimen identified four white firm masses with diameters ranging from 1 to 2 cm. These lesions were composed of hyaline connective tissue, which did not stain with either CD34 or CD117, and no viable tumour cells were identified in the whole specimens (fig 1C–E). Imatinib was suspended and after 24 months of follow up there is no evidence of local or distant recurrence. This is, to our knowledge, the first report of a complete pathological response of a GIST treated with imatinib.

12 August 2011 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
IFInês Francisco
Inês Francisco
CACristina Albuquerque
Cristina Albuquerque
PLPedro Lage
Pedro Lage
HBHélio Belo
Hélio Belo
IVInês Vitoriano
Inês Vitoriano
APAntónio Dias Pereira
António Dias Pereira

10 July 2012 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
MSMiguel Serrano
Miguel Serrano
PLPedro Lage
Pedro Lage
SBSara Belga
Sara Belga
BFBruno Filipe
Bruno Filipe
IFInês Francisco
Inês Francisco
APAntónio Dias Pereira
António Dias Pereira

1 June 2008 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
PDF file
SFSara Ferreira
Sara Ferreira
ICIsabel Claro
Isabel Claro
PLPedro Lage
Pedro Lage
BFBruno Filipe
Bruno Filipe
RFRicardo Fonseca
Ricardo Fonseca
CLCarlos Nobre Leitão
Carlos Nobre Leitão
Original Bethesda Guidelines proposed microsatellite instability analysis in colorectal adenomas from patients younger than aged 40 years to identify new cases of Lynch syndrome. We intended to evaluate the characteristics of colorectal adenomas from patients younger than aged 40 years to determine their microsatellite instability status and to correlate it with germline mutations inMLH1andMSH2genes. Seventy-two adenomas from 58 patients were analyzed. Family history of colorectal cancer, location, and histology of adenomas were evaluated. Microsatellite instability testing was performed with BAT26 only or with the complete Bethesda panel. Germline mutational analysis was performed inMLH1andMSH2genes. Thirty-five patients had a family history of colorectal cancer and 16 of them belonged to Amsterdam Criteria positive families. The remaining 23 presented with sporadic adenomas. Microsatellite instability was found in seven adenomas from seven different patients, all belonging to Amsterdam Criteria-positive families. In six of these patients, a pathogenic germline mutation was identified. Adenomas diagnosed before aged 40 years presented microsatellite instability only in patients from families with clinical criteria for Lynch syndrome. According to our results, to detect new cases of Lynch syndrome, family history is more important than microsatellite instability testing in adenomas from young patients.

28 December 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
AHAna Hipólito
Ana Hipólito
CMCindy Mendes
Cindy Mendes
FMFilipa Martins
Filipa Martins
ILIsabel Lemos
Isabel Lemos
IFInês Francisco
Inês Francisco
Jacinta SerpaJacinta Serpa
Jacinta Serpa
Lung cancer is a lethal disease with no truly efficient therapeutic management despite the progresses, and metabolic profiling can be a way of stratifying patients who may benefit from new therapies. The present study is dedicated to profiling cysteine metabolic pathways in NSCLC cell lines and tumor samples. This was carried out by analyzing hydrogen sulfide (H2S) and ATP levels, examining mRNA and protein expression patterns of cysteine catabolic enzymes and transporters, and conducting metabolomics analysis using nuclear magnetic resonance (NMR) spectroscopy. Selenium–chrysin (SeChry) was tested as a therapeutic alternative with the aim of having an effect on cysteine catabolism and showed promising results. NSCLC cell lines presented different cysteine metabolic patterns, with A549 and H292 presenting a higher reliance on cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) to maintain H2S levels, while the PC-9 cell line presented an adaptive behavior based on the use of mercaptopyruvate sulfurtransferase (MST) and cysteine dioxygenase (CDO1), both contributing to the role of cysteine as a pyruvate source. The analyses of human lung tumor samples corroborated this variability in profiles, meaning that the expression of certain genes may be informative in defining prognosis and new targets. Heterogeneity points out individual profiles, and the identification of new targets among metabolic players is a step forward in cancer management toward personalized medicine.

29 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JGJoana Guerra
Joana Guerra
CPCarla Pinto
Carla Pinto
PPPedro Pinto
Pedro Pinto
MPManuela Pinheiro
Manuela Pinheiro
CSCatarina Gomes Rodrigues Santos
Catarina Gomes Rodrigues Santos
MTManuel R. Teixeira
Manuel R. Teixeira
The most well-characterized hereditary form of gastric cancer is hereditary diffuse gastric cancer (HDGC), an autosomal dominant syndrome characterized by an increased risk of diffuse gastric and lobular breast cancer. HDGC is predominantly caused by germline pathogenic variants in the CDH1 gene, and more rarely in the CTNNA1 gene. Furthermore, the International Gastric Cancer Linkage Consortium (IGCLC) guidelines do not clarify whether or not mixed gastric cancer (with a diffuse component) should be considered in the HDGC genetic testing criteria. We aimed to evaluate the contribution of CTNNA1 and CTNND1 germline variants to HDGC. Additionally, we also intended to compare the frequencies of CDH1 and CTNNA1 (and eventually CTNND1) germline variants between patients with diffuse and mixed gastric carcinomas to evaluate if genetic testing for these genes should or should not be considered in patients with the latter. We analyzed the CDH1 gene in 67 cases affected with early-onset/familial mixed gastric carcinomas and the CTNNA1 and CTNND1 genes in 208 cases with diffuse or mixed gastric cancer who had tested negative for CDH1 pathogenic germline variants. A deleterious CTNNA1 germline variant was found in 0.7% (1/141) of diffuse gastric cancer patients meeting the 2020 IGCLC criteria, as compared to the rate of 2.8% of CDH1 deleterious variants found by us in this setting. No deleterious variants were found in CTNND1, but six variants of uncertain significance were identified in this gene. We did not find any pathogenic CDH1, CTNNA1 or CTNND1 variant in index patients with early-onset/familial mixed gastric cancer, so there is no evidence that supports including this tumor type in the testing criteria for germline variants in these genes. The role of the CTNND1 gene in inherited gastric cancer predisposition is still unclear.